+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030- Product Image
Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030- Product Image
Sale

Tuberculosis Drugs Market by Drug Class, Distribution Channel, Route Of Administration, Treatment Regimen, Tuberculosis Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4985928
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Drugs Market grew from USD 2.04 billion in 2024 to USD 2.18 billion in 2025. It is expected to continue growing at a CAGR of 6.30%, reaching USD 2.95 billion by 2030.

Setting the Stage for a New Era in Tuberculosis Treatment

The global fight against tuberculosis has entered a pivotal stage, marked by intensified research, novel therapeutic breakthroughs, and evolving policy landscapes. As incidence rates shift and drug-resistant strains emerge, stakeholders across pharmaceutical development, regulatory bodies, and healthcare delivery systems must navigate an increasingly complex environment. In this landscape, an accurate understanding of market dynamics and emerging trends is essential to inform strategic decisions and accelerate the adoption of life-saving therapies.

This report delivers an incisive overview of the current state of tuberculosis drug development and commercialization, contextualized within recent epidemiological data and policy shifts. It synthesizes insights from leading experts, clinical trial outcomes, and supply chain analyses to chart the course of innovation from first-line therapies through advanced treatment regimens. By spotlighting the forces driving market transformation, this introduction establishes the foundation for a comprehensive exploration of tariff implications, segmentation nuances, regional variances, and competitive positioning. Ultimately, the goal is to equip decision-makers with the clarity and foresight needed to advance patient care and realize sustainable growth in the tuberculosis drug market.

Emerging Forces Reshaping the Tuberculosis Drug Landscape

Over the past decade, the tuberculosis drug landscape has experienced profound shifts driven by scientific advances, regulatory recalibrations, and investment realignments. Breakthrough chemotherapeutics targeting drug-resistant strains have transitioned from proof of concept to clinical practice, prompting a redefinition of treatment algorithms and enabling regimen personalization. Concurrently, accelerated approval pathways have reduced time to market, fostering an environment in which novel agents rapidly gain traction alongside established first-line therapies.

Supply chain resilience has become a strategic imperative, as global disruptions have underscored the vulnerability of active pharmaceutical ingredient sourcing and formulation manufacturing. Manufacturers are diversifying supplier networks and adopting flexible production models to safeguard continuity of supply. On the policy front, outcome-based reimbursement models are gaining momentum, incentivizing value-driven approaches and reinforcing the need for robust pharmacoeconomic evidence. These transformative forces collectively signal a transition toward an era in which innovation, agility, and value demonstration define competitive advantage in the tuberculosis drug market.

Navigating the Impact of 2025 US Tariffs on Tuberculosis Therapies

The imposition of new United States tariffs in 2025 marks a significant inflection point for global tuberculosis drug trade flows. Historically, cost-sensitive generics and fixed dose combinations have been imported at minimal tariff rates, enabling widespread access in low- and middle-income countries. With the revised duty structure, import costs for key active ingredients and finished formulations have increased, creating downward pressure on affordability and potentially constraining distribution in high-burden regions.

In response, pharmaceutical companies are recalibrating supply strategies by onshoring certain manufacturing operations and negotiating long-term contracts to lock in favorable input pricing. These adjustments aim to mitigate margin erosion and ensure uninterrupted supply, yet they also entail capital expenditures and logistical complexities. Meanwhile, public sector procurement agencies are reassessing tender frameworks to account for the new cost landscape, potentially prioritizing cost containment over product differentiation. As a result, the tariff adjustments of 2025 are poised to reshape pricing dynamics, influence formulation choices, and drive innovative partnerships that can absorb or offset the additional import burden.

Unveiling Critical Segmentation Dimensions in the Tuberculosis Drug Market

A nuanced appreciation of market segmentation reveals the critical levers that will determine future growth trajectories. For drug class, first-line therapies remain the cornerstone of treatment, with fixed dose combinations consolidating multiple agents into standardized regimens. These combinations span formulations that integrate four, three, or two drugs, offering enhanced adherence potential compared to single drug preparations. Simultaneously, novel therapies such as Bedaquiline, Delamanid, and Pretomanid are extending the boundaries of efficacy against resistant tuberculosis strains. Complementing these are second-line options, which rely on fluoroquinolones and injectable aminoglycosides to address complex cases that no longer respond to conventional regimens.

Distribution channels are likewise evolving, with hospital pharmacies continuing to serve as treatment hubs for complex cases, online pharmacies enhancing convenience and accessibility, and retail pharmacies ensuring broad community-level availability. The choice between injectable and oral routes of administration further shapes patient adherence and health system resource allocation. Treatment regimens, whether individualized based on patient-specific resistance profiles, designed for extended courses, or structured into short intensive cycles, define therapeutic effectiveness and cost implications. Finally, the delineation between extrapulmonary and pulmonary tuberculosis underscores the necessity for tailored diagnostic and treatment approaches. Taken together, these segmentation dimensions clarify the competitive landscape and illuminate targeted opportunities for market penetration and product differentiation.

Regional Dynamics Driving Tuberculosis Drug Adoption Worldwide

Geographic realities exert a profound influence on market uptake, policy frameworks, and investment priorities. Within the Americas, robust healthcare infrastructure and favorable reimbursement environments have facilitated early adoption of novel therapies, although pockets of access disparity persist in resource-limited areas. In Europe, Middle East & Africa, regulatory diversity and variable public funding mechanisms shape a mosaic of uptake patterns, with some markets pioneering outcome-based contracts while others adhere to more traditional tender processes.

Across the Asia-Pacific region, high disease burden and growing pharmaceutical manufacturing capacity intersect to create a dynamic ecosystem. Governments are actively supporting domestic production of both generics and new chemical entities, driving competition and cost efficiencies. At the same time, public-private partnerships are scaling community-based screening and treatment programs, expanding access to advanced regimens. Understanding these regional dynamics is essential for stakeholders aiming to tailor market entry strategies, forge strategic alliances, and navigate the intricate balance between affordability, innovation, and patient impact.

Profiling Leading Players in the Global Tuberculosis Drug Sector

A cadre of multinational pharmaceutical leaders and specialized biotech firms now dominates the tuberculosis drug arena. Established industry incumbents leverage deep clinical development experience and global distribution networks to reinforce their positions in both legacy first-line therapies and emerging novel treatments. Meanwhile, agile niche players focus on advanced pipelines, often collaborating with public sector funders and academic institutions to accelerate proof-of-concept studies and gain early regulatory engagement.

Strategic partnerships and licensing agreements have proliferated as companies seek to combine proprietary assets with complementary capabilities in manufacturing, regulatory affairs, and market access. Investment activity remains elevated, with venture capitalists and development finance institutions underwriting projects that promise to address unmet medical needs and generate meaningful health economic returns. As competition intensifies, differentiation through real-world evidence generation, digital adherence monitoring, and value-based contracting is becoming increasingly decisive in securing institutional and payer support.

Strategic Actions for Industry Leaders to Seize Market Opportunities

Industry leaders must adopt a multi-pronged approach to capitalize on emerging opportunities while safeguarding against evolving risks. First, strengthening supply chain resilience through diversified manufacturing footprints and strategic inventory buffers will mitigate the impact of external shocks such as tariff fluctuations or raw material shortages. Second, investing in real-world evidence studies and health economic models will enhance the value proposition of novel and combination therapies within outcome-driven reimbursement environments.

Third, engaging early with regulatory authorities to secure accelerated approvals and adaptive pathways can shorten time to market in priority regions. Fourth, forming collaborative alliances-including co-development, licensing, and shared-risk agreements-enables access to complementary expertise and resources, thereby distributing development costs and amplifying market reach. Finally, embracing digital health solutions to monitor adherence, collect patient-reported outcomes, and support decentralized treatment delivery will strengthen patient engagement and optimize therapeutic outcomes.

Rigorous Research Framework Underpinning the Analysis

The analysis underpinning this report integrates a robust blend of primary and secondary research methodologies. Expert interviews with clinicians, policymakers, procurement officers, and patient advocacy representatives provided qualitative insights into treatment preferences, access barriers, and emerging clinical needs. A systematic review of regulatory filings, clinical trial registries, and patent databases delivered quantitative validation of pipeline progress and market authorizations.

Market intelligence derived from procurement data, tender announcements, and industry financial disclosures was triangulated with socioeconomic indicators and epidemiological statistics to contextualize demand drivers and supply constraints. Segmentation analyses were constructed using cross-tabulations of drug class, distribution channel, route of administration, treatment regimen, and tuberculosis type, ensuring a comprehensive understanding of market nuances. Geospatial mapping techniques highlighted regional adoption patterns, while competitor benchmarking offered a clear view of strategic positioning. This rigorous framework ensures that the findings and recommendations presented herein rest on an unassailable evidentiary foundation.

Consolidating Insights to Chart the Future of Tuberculosis Treatment

The evolving tuberculosis drug market presents a convergence of scientific innovation, policy evolution, and strategic complexity. Novel therapeutics are rewriting treatment paradigms, while tariff adjustments and regional divergences continue to reshape access and affordability. By dissecting segmentation dimensions and profiling leading companies, this report has illuminated the levers that will drive competitive advantage and patient impact in the coming years.

As stakeholders confront the dual imperatives of innovation and cost containment, evidence-based recommendations offer a strategic roadmap for navigating uncertainty and capitalizing on growth opportunities. From reinforcing supply chain resilience to harnessing digital health technologies, the pathways to success are clear yet require disciplined execution and collaborative engagement across the public and private sectors. Ultimately, the insights presented here aim to empower decision-makers to accelerate the delivery of effective tuberculosis treatments and improve outcomes for patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • First Line
      • Fixed Dose Combination
        • Four Drug Combination
        • Three Drug Combination
        • Two Drug Combination
      • Single Drug Preparations
    • Novel
      • Bedaquiline
      • Delamanid
      • Pretomanid
    • Second Line
      • Fluoroquinolones
      • Injectable Aminoglycosides
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Route Of Administration
    • Injectable
    • Oral
  • Treatment Regimen
    • Individualized Regimen
    • Long Course
    • Short Course
  • Tuberculosis Type
    • Extrapulmonary
    • Pulmonary
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • Lupin Limited
  • Cipla Limited
  • Viatris Inc
  • Sun Pharmaceutical Industries Limited
  • Otsuka Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Teva Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tuberculosis Drugs Market, by Drug Class
8.1. Introduction
8.2. First Line
8.2.1. Fixed Dose Combination
8.2.1.1. Four Drug Combination
8.2.1.2. Three Drug Combination
8.2.1.3. Two Drug Combination
8.2.2. Single Drug Preparations
8.3. Novel
8.3.1. Bedaquiline
8.3.2. Delamanid
8.3.3. Pretomanid
8.4. Second Line
8.4.1. Fluoroquinolones
8.4.2. Injectable Aminoglycosides
9. Tuberculosis Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Tuberculosis Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
11. Tuberculosis Drugs Market, by Treatment Regimen
11.1. Introduction
11.2. Individualized Regimen
11.3. Long Course
11.4. Short Course
12. Tuberculosis Drugs Market, by Tuberculosis Type
12.1. Introduction
12.2. Extrapulmonary
12.3. Pulmonary
13. Americas Tuberculosis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Tuberculosis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Tuberculosis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. Lupin Limited
16.3.3. Cipla Limited
16.3.4. Viatris Inc
16.3.5. Sun Pharmaceutical Industries Limited
16.3.6. Otsuka Pharmaceutical Co., Ltd.
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Teva Pharmaceutical Industries Limited
16.3.9. Glenmark Pharmaceuticals Limited
16.3.10. F. Hoffmann-La Roche Ltd
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TUBERCULOSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. TUBERCULOSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FOUR DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY THREE DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TWO DRUG COMBINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SINGLE DRUG PREPARATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PRETOMANID, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 60. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 62. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 63. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 66. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 113. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 116. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 117. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 125. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 126. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 142. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 143. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 144. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 145. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 148. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 149. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 151. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 152. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 153. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 157. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 187. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 188. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 189. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 193. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 203. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 205. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 206. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 207. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 208. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 211. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 212. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 214. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 215. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 216. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 220. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 239. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 242. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 243. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 244. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 247. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 248. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 250. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 251. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 252. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 253. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 256. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 266. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 268. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 269. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 270. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 274. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 275. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 276. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 277. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 278. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 279. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 280. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 283. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 303. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 305. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 306. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 307. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 308. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 311. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 314. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 315. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 316. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 317. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 320. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 321. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 322. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 323. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 324. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 325. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 326. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 328. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 329. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED DOSE COMBINATION, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 341. SOUTH

Companies Mentioned

The companies profiled in this Tuberculosis Drugs market report include:
  • Johnson & Johnson
  • Lupin Limited
  • Cipla Limited
  • Viatris Inc
  • Sun Pharmaceutical Industries Limited
  • Otsuka Pharmaceutical Co., Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Teva Pharmaceutical Industries Limited
  • Glenmark Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.95 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 178 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market 2025-2033 - Product Image

Anti-Tuberculosis Therapeutics Market 2025-2033

  • Report
  • 146 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Tuberculosis Therapeutics Market Report 2025 - Product Image

Tuberculosis Therapeutics Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Tuberculosis Drug Market

The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy. The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.